alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.1




CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Annual Report of Anaren, Inc. (the “Company”) on Form 10-K for the year ended June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lawrence A. Sala, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:




(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and




(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.






/s/ Lawrence A. Sala


Lawrence A. Sala


President and Chief Executive Officer


(Principal Executive Officer)




August 11, 2011




A signed original of this written statement required by Section 906 has been provided to Anaren, Inc. and will be retained by Anaren, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 18-4569

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

EMORY CHILES,

Defendant - Appellant.

Appeal from the United States District Court for the Northern District of West Virginia, 

at Clarksburg. Irene M. Keeley, Senior District Judge. (1:18-cr-00007-IMK-MJA-1)

Submitted: March 28, 2019 Decided: April 23, 2019

Before NIEMEYER, KING, and KEENAN, Circuit Judges.

Affirmed by unpublished per curiam opinion.

L. Richard Walker, Senior Litigator, Clarksburg, West Virginia, Kristen Leddy, Assistant 

Federal Public Defender, OFFICE OF THE FEDERAL PUBLIC DEFENDER, 

Martinsburg, West Virginia, for Appellant. William J. Powell, United States Attorney, 

Zelda E. Wesley, Assistant United States Attorney, OFFICE OF THE UNITED STATES 

ATTORNEY, Clarksburg, West Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Following a jury trial, Emory Chiles was convicted of possession with intent to 

distribute heroin, use of a firearm during and in relation to a drug trafficking offense, and 

unlawful possession of a firearm. The district court sentenced Chiles to a total 

imprisonment term of 360 months. On appeal, Chiles challenges the propriety of the 

traffic stop of a vehicle in which Chiles was a passenger, the reasonableness of the 

duration of the stop, and whether the officers had reasonable suspicion to justify the frisk 

of him, which resulted in the officer discovering that Chiles was in possession of a 

firearm. 

We review the factual findings underlying the denial of a motion to suppress for 

clear error and the court’s legal conclusions de novo. United States v. Bullette, 854 F.3d 

261, 265 (4th Cir. 2017). Additionally, we “construe the evidence in the light most 

favorable to the government—the prevailing party below.” Id. (internal quotation marks 

omitted).

With these standards in mind, we have considered carefully the arguments raised 

by Chiles on appeal and conclude for the reasons stated by the district court that the court 

properly denied the motion to suppress. United States v. Chiles, No. 1:18-cr-00007-IMKMJA-1 (N.D.W. Va. Apr. 13, 2018). Accordingly, we affirm the judgment of the district 

court entered on August 7, 2018. We dispense with oral argument because the facts and 

legal contentions are adequately presented in the materials before this court and argument 

would not aid the decisional process.

AFFIRMED
II 

111TH CONGRESS 

2D SESSION S. 3094 

To allow individuals to elect to opt out of the Medicare part A benefits. 

IN THE SENATE OF THE UNITED STATES 

MARCH 9, 2010 

Mr. BUNNING introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To allow individuals to elect to opt out of the Medicare 

part A benefits. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ALLOWING INDIVIDUALS TO ELECT TO OPT 

4 OUT OF THE MEDICARE PART A BENEFIT. 

5 Notwithstanding any other provision of law, in the 

6 case of an individual who elects to opt out of benefits 

7 under part A of title XVIII of the Social Security Act, 

8 such individual shall not be required to— 

9 (1) opt out of benefits under title II of such Act 

10 as a condition for making such election; and 


dcolon on DSK2BSOYB1PROD with BILLS
2 

•S 3094 IS

1 (2) repay any amount paid under such part A 

2 for items and services furnished prior to making 

3 such election. 

Æ 


dcolon on DSK2BSOYB1PROD with BILLS
Exhibit 10.1

    

     

    

    AMENDMENT

    TO THE

    DONEGAL GROUP INC.

    2021 EMPLOYEE STOCK PURCHASE PLAN

     

    This Amendment is adopted this 21st day of July, 2022.

     

    WHEREAS, Donegal Group Inc. (the “Company”) maintains the Donegal Group Inc, Employee Stock Purchase Plan (the
        “Plan”) for the benefit of employees of Donegal Mutual Insurance Company; and

     

    WHEREAS, pursuant to Section 13 of the Plan, the Company has reserved the right to modify or amend the Plan; and

     

    WHEREAS, the Company desires to amend the Plan to reflect certain changes to the maximum number of shares that a
        participant may purchase under the Plan.

     

    NOW, THEREFORE, BE IT

     

    RESOLVED, that the Plan is hereby amended as follows:

     

    1.           Section 8 of the Plan is amended by the addition of the following paragraph at the end of Section 8:

     

    Section 1.          Purchase of Shares.

    

    

    At the end of each Subscription Period, this Plan shall be deemed to have granted to the participant an option for as many shares as he or she will be able to purchase with the
      amounts credited to his or her Plan Account during his or her participation in that Subscription Period. Notwithstanding the foregoing, no participant may purchase more than 3,000 shares of stock during any single Subscription Period. This number may
      be adjusted as permitted pursuant to Section 12 of the Plan.

    

    

    *          *          *          *

     

    IN WITNESS WHEREOF, Donegal Group Inc. has caused this Amendment to be executed as of the date first set forth above.

     

    	 	
            DONEGAL GROUP INC.

          
	 	 	 
	 	
            By:

          	
            /s/ Kevin G. Burke

          
	 	 	
            Kevin G. Burke

          
	 	 	
            President & Chief Executive Officer
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2557 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2557

         To suspend temporarily the duty on metsulfuron-methyl.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            October 30, 2009

  Mr. Burris introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
         To suspend temporarily the duty on metsulfuron-methyl.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. METSULFURON-METHYL.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.01.00       Methyl 2-[[[[(4-    Free         No change        No change        On or before 12/ ''.
                          methoxy-6-methyl-                                                  31/2011.......
                          1,3,5-triazin-2-
                          yl)
                          amino]carbonyl]am
                          ino]
                          sulfonyl]benzoate
                          (CAS No. 74223-64-
                          6), in pure form
                          or in forms or
                          packings for
                          retail sale,
                          preparations or
                          articles
                          (provided for in
                          subheadings
                          2935.00.75 or
                          3808.30.15)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
COURT OF APPEALS FOR THE

FIRST DISTRICT OF TEXAS AT HOUSTON

ORDER

Appellate case name: Henry Rangel v. The State of Texas

Appellate case number: 01-18-00273-CR

Trial court case number: CR13465

Trial court: 355th District Court of Hood County

Appellant’s court-appointed counsel, Lukas A. Lawrence, filed a motion to 

withdraw and appellate brief on July 25, 2018, concluding that the above-referenced appeal 

is frivolous. See Anders v. California, 386 U.S. 738, 744, 87 S. Ct. 1396, 1400 (1967). On 

August 17, 2018, appellant, Henry Rangel, acting pro se, filed a pro se motion for access 

to the appellate record to prepare a response and also requested a 30-day extension of time 

to file his pro se Anders brief response. See Kelly v. State, 436 S.W.3d 313, 315, 318–20 

(Tex. Crim. App. 2014).

Accordingly, the Court grants appellant’s motion and orders the district clerk, no 

later than 10 days from the date of this order, to mail a copy of the clerk’s and reporter’s 

records to the pro se appellant. The district clerk shall further certify to this Court, within 

15 days of the date of this order, the date upon which delivery of the records to the appellant 

is made.

Furthermore, the Court grants appellant’s motion for an extension of time to file a

pro se Anders response. Appellant’s pro se response to his counsel’s Anders brief shall be 

filed within 45 days of the date of this order.

Finally, the Court orders appellant’s court-appointed counsel, Lukas A. Lawrence, 

to respond to the pro se appellant’s cover letter, filed with his motion on August 17, 2018, 

within ten days of the date of this Order and certify.

It is so ORDERED.

Judge’s signature: /s/ Evelyn V. Keyes

  Acting individually  Acting for the Court

Date: August 28, 2018
II 

111TH CONGRESS 

1ST SESSION S. 2904 

To amend title 10, United States Code, to require emergency contraception 

to be available at all military health care treatment facilities. 

IN THE SENATE OF THE UNITED STATES 

DECEMBER 17, 2009 

Mr. FRANKEN (for himself, Ms. SNOWE, Mr. KERRY, Mr. LAUTENBERG, Mr. 

FEINGOLD, Mr. MENENDEZ, Mr. DURBIN, Mrs. GILLIBRAND, Mrs. FEINSTEIN, Mrs. BOXER, Mrs. MCCASKILL, Mr. HARKIN, and Mr. SCHUMER) 

introduced the following bill; which was read twice and referred to the 

Committee on Armed Services 

A BILL 

To amend title 10, United States Code, to require emergency 

contraception to be available at all military health care 

treatment facilities. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Compassionate Care 

5 for Servicewomen Act’’. 


srobinson on DSKHWCL6B1PROD with BILLS
2 

•S 2904 IS

1 SEC. 2. REQUIREMENT TO MAKE AVAILABLE EMERGENCY 

2 CONTRACEPTION AT ALL MILITARY HEALTH 

3 CARE TREATMENT FACILITIES. 

4 Section 1074g(a) of title 10, United States Code, is 

5 amended by adding at the end the following new para6 graph: 

7 ‘‘(9)(A) Emergency contraception in drug form shall 

8 be included on the basic core formulary of the uniform 

9 formulary, notwithstanding any provision of law or regula10 tion requiring that only drugs ordered or prescribed by 

11 a physician (or other authorized provider) may be included 

12 in the uniform formulary. Emergency contraception in 

13 other than drug form may also be included on the basic 

14 core formulary, notwithstanding any such provision. 

15 ‘‘(B) Nothing in subparagraph (A) may be construed 

16 to require emergency contraception to be covered under 

17 the pharmacy benefits program. 

18 ‘‘(C) Notwithstanding paragraph (4), prior author19 ization shall not be required for emergency contraception. 

20 Nothing in the preceding sentence may be construed as 

21 waiving any provision of the Federal Food, Drug, and Cos22 metic Act (21 U.S.C. 301 et seq.) or any other provision 

23 of law administered by the Food and Drug Administra24 tion, including rules and orders of such Administration in 

25 effect at any time under such Act or other provisions of 

26 law. 


srobinson on DSKHWCL6B1PROD with BILLS
3 

•S 2904 IS

1 ‘‘(D) In this paragraph, the term ‘emergency contra2 ception’ means a drug, drug regimen, or device that is— 

3 ‘‘(i) approved by the Food and Drug Adminis4 tration to prevent pregnancy; and 

5 ‘‘(ii) used postcoitally.’’. 

Æ 


srobinson on DSKHWCL6B1PROD with BILLS
Exhibit 32-1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Financial Report of NoFire Technologies,
Inc. on Form 10QSB for the Quarter ended 11/30/05 as filed
with the Securities and Exchange Commission on the date hereof,
I, Sam Gottfried, Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Form 10QSB fully complies with the requirements of Section
13 (a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.
78m or 78o(d)); and

(2) The information contained in the Form 10QSB fairly presents,
in all material respects, the financial condition and results of
operations of the Company.



Dated: January 12,2006

Name  /s/ Sam Gottfried (CEO)


A signed original of this written statement required by Section 906,
or other document authenticating, acknowledging, or otherwise adopting
 the signature that  appears in typed form within the electronic
version of this written  statement required by Section 906, has been
provided to NoFire Technologies,
Inc. and will be retained by NoFire Technologies, Inc. and furnished
to the Securities and Exchange Commission or its staff upon request.







Exhibit 32-2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Financial Report of NoFire Technologies,
Inc. on Form 10QSB for the Quarter ended 11/30/05 as filed
with the Securities and Exchange Commission on the date hereof,
I, Sam Oolie, Chief Financial Officer of the Company,
certify, pursuant to 18 U.S.C. 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Form 10QSBfully complies with the requirements of Section
13 (a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.
78m or 78o(d)); and


(2) The information contained in the Form 10QSB fairly presents,
in all material respects, the financial condition and results of
operations of the Company.



Dated: January 12,2006

Name  /s/ Sam Oolie (CFO)


A signed original of this written statement required by Section 906,
or other document authenticating, acknowledging, or otherwise adopting
 the signature that  appears in typed form within the electronic
version of this written  statement required by Section 906, has been

provided to NoFire Technologies,
Inc. and will be retained by NoFire Technologies, Inc. and furnished
to the Securities and Exchange Commission or its staff upon request.
## F IRST 

## D ISTRICT 

## C OURT OF 

## A PPEAL 

## S TATE OF 

## F LORIDA

_____________________________

No. 1 D 2 0 2 3

- 1889

_____________________________

M ARIO D ANIELS ,
Appellant,

v.

S TATE OF F LORIDA ,
Appellee.

_____________________________

On appeal from the Circuit Court for Leon County

. Joshua Hawkes , Judge

.

February 21, 2024

P ER C URIAM

.

D ISMISSED

. See Robinson v. State , 255 So. 3d 907 (Fla. 1st DCA 2018) (“The order of the circuit court deciding that Appellant is not entitled to postconviction discovery is not among the class of orders independently appealable by a defendant pursuant to Florida Rule of Appellate Procedure 9.140(b)(1).”).

L EWIS , R AY , and K ELSEY , JJ., concur.2 _____________ ________________ Not final until disposition of any timely and authorized motion under Fla. R. App. P. 9.330 or 9.331

.

_____________________________

Mario Daniels

, pro se, Appellant.

Ashley Moody, Attorney General, Tallahassee

, for Appellee.
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA,

 Plaintiff - Appellee,

 v.

JOSEPH A. McDANIELS,

 Defendant - Appellant.

No. 13-30026

D.C. No. 2:12-cr-00185-JLR

MEMORANDUM*

Appeal from the United States District Court

for the Western District of Washington

James L. Robart, District Judge, Presiding

Submitted December 17, 2013** 

Before: GOODWIN, WALLACE, and GRABER, Circuit Judges.

Joseph A. McDaniels appeals from the district court’s judgment and

challenges the 113-month prison sentence and three-year term of supervised

release imposed following his guilty-plea conviction for interstate transportation

FILED

DEC 30 2013

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS

 * This disposition is not appropriate for publication and is not precedent

except as provided by 9th Cir. R. 36-3.

 ** The panel unanimously concludes this case is suitable for decision

without oral argument. See Fed. R. App. P. 34(a)(2).
for prostitution, in violation of 18 U.S.C. § 2421. We have jurisdiction under 28

U.S.C. § 1291, and we affirm.

 McDaniels contends the government breached the plea agreement by

advocating for a three-year term of supervised release in addition to the agreedupon term of imprisonment. We review de novo whether the government breached

the plea agreement, see United States v. Whitney, 673 F.3d 965, 970 (9th Cir.

2012), and determine that it did not. The government performed its obligation

under the agreement by recommending a 120-month term of imprisonment. 

Moreover, the district court properly concluded that the recommendation of a

three-year term of supervised release did not breach the plea agreement, where the

plea agreement advised McDaniels that a term of supervised release was one of the

statutory penalties for his offense, and was silent regarding whether the

government could recommend a term of supervised release. See United States v.

Franco-Lopez, 312 F.3d 984, 989 (9th Cir. 2002) (when construing a plea

agreement, this court must determine what the defendant reasonably believed to be

the terms of the plea agreement at the time of the plea).

AFFIRMED.

2 13-30026
[Federal Register Volume 74, Number 5 (Thursday, January 8, 2009)]
[Notices]
[Page 845]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-126]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice 6476]


Certification Related to Libya Under Section 654(b) of the State, 
Foreign Operations, and Related Programs Appropriations Act, 2008 (Div. 
J. Pub. L. 110-161)

    Summary: The Secretary of State certified to the Committees on 
Appropriation on December 24, 2008 that Libya has met the requirements 
stipulated in Section 654(b) of the State, Foreign Operations, and 
Related Programs Appropriations Act of 2008.

    Dated: January 2, 2009.
Jeffrey Feltman,
Acting Assistant Secretary of State for Near Eastern Affairs, 
Department of State.
 [FR Doc. E9-126 Filed 1-7-09; 8:45 am]
BILLING CODE 4710-31-P
**Exhibit11**

 

**Calculationof Basic Earnings Per Share**

 
|                                                  |   | **Year Ended**            |       |
|-------------------------------------------------------|--------|---------------------------|------------|
|                                                  |   | **January 3,  2004** |       | **December 28,  2002** |   | **December 31,  2001** |   |
|                                                  |   |                      |       |   |   |   |   |
| Net loss                                              |   | $                         | (1,524,000 | ) | $ | (21,031,000 | ) | $ | (2,980,000 | ) |
|                                                  |   |                      |       |   |   |   |   |
| Weighted average number of common shares  outstanding |   | 24,201,000                |       | 24,198,000 |   | 24,196,000 |   |
|                                                  |   |                      |       |   |   |   |   |
| Basic loss per share                                  |   | $                         | (.06       | ) | $ | (.87 | ) | $ | (.12 | ) |

 

 

**Calculationof Diluted Earnings Per Share**

 
|                                                                                     |   | **Year Ended**            |       |
|------------------------------------------------------------------------------------------|--------|---------------------------|------------|
|                                                                                     |   | **January 3,  2004** |       | **December 28,  2002** |   | **December 31,  2001** |   |
|                                                                                     |   |                      |       |   |   |   |   |
| Net loss                                                                                 |   | $                         | (1,524,000 | ) | $ | (21,031,000 | ) | $ | (2,980,000 | ) |
|                                                                                     |   |                      |       |   |   |   |   |
| Weighted average number of common shares  outstanding                                    |   | 24,201,000                |       | 24,198,000 |   | 24,196,000 |   |
|                                                                                     |   |                      |       |   |   |   |   |
| Dilutive effect of stock options  outstanding after application of treasury stock method |   | 0                         |       | 0 |   | 0 |   |
|                                                                                     |   |                      |       |   |   |   |   |
| Adjusted weighted average shares                                                         |   | 24,201,000                |       | 24,198,000 |   | 24,196,000 |   |
|                                                                                     |   |                      |       |   |   |   |   |
| Diluted loss per share                                                                   |   | $                         | (.06       | ) | $ | (.87 | ) | $ | (.12 | ) |

 

1

----